|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral suspension
|
|
gptkbp:approves
|
gptkb:FDA
1950s
|
|
gptkbp:atccode
|
J01 EB01
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:brand
|
gptkb:Gantrisin
|
|
gptkbp:can_be_combined_with
|
gptkb:trimethoprim
other antibiotics
antifolates
|
|
gptkbp:casnumber
|
144-83-2
|
|
gptkbp:chemical_formula
|
C10 H11 N3 O3 S
|
|
gptkbp:clinical_trial
|
Phase IV
|
|
gptkbp:contraindication
|
pregnancy
newborns
severe liver disease
severe renal impairment
G6 PD deficiency
|
|
gptkbp:developed_by
|
gptkb:Parke-Davis
|
|
gptkbp:dosage_form
|
gptkb:tablet
suspension
|
|
gptkbp:formulation
|
gptkb:tablet
gptkb:liquid
suspension
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gantrisin
|
|
gptkbp:ingredients
|
gptkb:sulfisoxazole
|
|
gptkbp:interacts_with
|
gptkb:methotrexate
gptkb:warfarin
oral hypoglycemics
|
|
gptkbp:is_part_of
|
sulfonamide class
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
inhibits bacterial folic acid synthesis
|
|
gptkbp:related_to
|
gptkb:sulfadiazine
gptkb:sulfamethoxazole
gptkb:sulfamethoxazole/trimethoprim
|
|
gptkbp:requires
|
gptkb:true
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
nausea
vomiting
diarrhea
liver toxicity
skin rash
hemolytic anemia
kidney toxicity
hypersensitivity reaction
crystalluria
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:used_for
|
bacterial infections
|
|
gptkbp:bfsParent
|
gptkb:sulfisoxazole
|
|
gptkbp:bfsLayer
|
8
|